Discover Nano,
Journal Year:
2025,
Volume and Issue:
20(1)
Published: April 24, 2025
Cancer
treatments
often
exploit
oxidative
stress
to
selectively
kill
tumour
cells
by
disrupting
their
lipid
peroxidation
membranes
and
inhibiting
antioxidant
enzymes.
However,
plays
a
dual
role
in
cancer
progression,
acting
as
both
promoter
suppressor.
Balancing
through
therapy
remains
challenge,
excessive
activity
may
compromise
the
efficacy
of
chemotherapy
radiotherapy.
This
review
explores
antioxidants
mitigating
while
maintaining
treatment
efficacy.
It
highlights
recent
advancements
nanotechnology-based
targeted
delivery
optimize
therapeutic
outcomes.
A
comprehensive
literature
was
conducted
using
reputable
databases,
including
PubMed,
Scopus,
Web
Science,
ScienceDirect.
The
search
focused
on
publications
from
past
five
years
(2020-2025),
supplemented
relevant
studies
earlier
years.
Keywords
such
"antioxidants,"
"lipid
peroxidation,"
"nanotechnology
therapy,"
"oxidative
stress"
were
utilized.
Relevant
articles
critically
analysed,
graphical
illustrations
created.
Emerging
evidence
suggests
that
nanoparticles,
liposomes,
polymeric
metal-organic
frameworks,
others,
can
effectively
encapsulate
control
release
minimizing
systemic
toxicity.
Stimuli-responsive
carriers
with
tumour-specific
targeting
mechanisms
further
enhance
delivery.
Studies
indicate
these
strategies
help
preserve
normal
cells,
mitigate
stress-related
damage,
improve
challenges
bioavailability,
stability,
potential
interactions
standard
therapies
remain.
Integrating
nanotechnology
antioxidant-based
interventions
presents
promising
approach
for
optimizing
therapy.
Future
research
should
focus
refining
modulation
strategies,
assessing
profiles
during
treatment,
employing
biomarkers
determine
optimal
dosing.
balanced
use
adverse
effects.
Pharmacological Research,
Journal Year:
2025,
Volume and Issue:
214, P. 107674 - 107674
Published: Feb. 27, 2025
Currently,
cancer
immunotherapy
strategies
are
primarily
formulated
based
on
the
patient's
present
condition,
representing
a
"static"
treatment
approach.
However,
progression
is
inherently
"dynamic,"
as
immune
environment
not
fixed
but
undergoes
continuous
changes.
This
dynamism
characterized
by
ongoing
interactions
between
tumor
cells
and
cells,
which
ultimately
lead
to
alterations
in
microenvironment.
process
can
be
effectively
elucidated
concept
of
immunoediting,
divides
development
into
three
phases:
"elimination,"
"equilibrium,"
"escape."
Consequently,
adjusting
regimens
these
distinct
phases
may
enhance
patient
survival
improve
prognosis.
Targeting
ferroptosis
an
emerging
area
immunotherapy,
our
findings
reveal
that
antioxidant
systems
associated
with
possess
dual
roles,
functioning
differently
across
immunoediting.
Therefore,
this
review
delve
role
system
progression.
It
also
propose
targeting
at
different
stages,
aiming
illuminate
significant
implications
various
for
immunotherapy.
Frontiers in Pharmacology,
Journal Year:
2025,
Volume and Issue:
16
Published: March 5, 2025
Cisplatin
is
a
widely
used
drug
for
the
treatment
of
solid
organ
cancer,
but
its
renal
toxicity
cannot
be
ignored.
Amentoflavone
(AME),
natural
flavonoid
compound,
has
remarkable
pharmacological
effects,
including
anti-inflammatory
and
antioxidative
effects.
The
effect
mechanism
AME
on
cisplatin-induced
acute
kidney
injury
(CI-AKI)
remain
unclear.
We
investigated
CI-AKI
using
HK-2
cell
line
C57BL/6
mice.
Renal
function,
tissue
damage,
molecular
markers
were
assessed
to
explore
effects
oxidative
stress
death
pathways.
In
vitro,
significantly
suppressed
cytotoxic
cisplatin
cells.
Furthermore,
inhibited
ferroptosis
PANoptosis
(apoptosis,
pyroptosis
necroptosis).
mice
with
induced
by
single
intraperitoneal
injection
cisplatin,
daily
administration
during
AKI
effectively
improved
function
alleviated
tubular
injury,
characterized
normalization
blood
urea
nitrogen
(BUN)
serum
creatinine
(SCr)
levels;
it
also
PANoptosis.
antioxidant
that
activates
Nrf2
pathway
both
in
vivo
vitro.
knockout
knockdown
cells,
protective
against
nephrotoxicity
disappeared.
However,
after
knockout,
completely
disappeared,
partially
via
related
Nrf2-dependent
regulation
Discover Nano,
Journal Year:
2025,
Volume and Issue:
20(1)
Published: April 24, 2025
Cancer
treatments
often
exploit
oxidative
stress
to
selectively
kill
tumour
cells
by
disrupting
their
lipid
peroxidation
membranes
and
inhibiting
antioxidant
enzymes.
However,
plays
a
dual
role
in
cancer
progression,
acting
as
both
promoter
suppressor.
Balancing
through
therapy
remains
challenge,
excessive
activity
may
compromise
the
efficacy
of
chemotherapy
radiotherapy.
This
review
explores
antioxidants
mitigating
while
maintaining
treatment
efficacy.
It
highlights
recent
advancements
nanotechnology-based
targeted
delivery
optimize
therapeutic
outcomes.
A
comprehensive
literature
was
conducted
using
reputable
databases,
including
PubMed,
Scopus,
Web
Science,
ScienceDirect.
The
search
focused
on
publications
from
past
five
years
(2020-2025),
supplemented
relevant
studies
earlier
years.
Keywords
such
"antioxidants,"
"lipid
peroxidation,"
"nanotechnology
therapy,"
"oxidative
stress"
were
utilized.
Relevant
articles
critically
analysed,
graphical
illustrations
created.
Emerging
evidence
suggests
that
nanoparticles,
liposomes,
polymeric
metal-organic
frameworks,
others,
can
effectively
encapsulate
control
release
minimizing
systemic
toxicity.
Stimuli-responsive
carriers
with
tumour-specific
targeting
mechanisms
further
enhance
delivery.
Studies
indicate
these
strategies
help
preserve
normal
cells,
mitigate
stress-related
damage,
improve
challenges
bioavailability,
stability,
potential
interactions
standard
therapies
remain.
Integrating
nanotechnology
antioxidant-based
interventions
presents
promising
approach
for
optimizing
therapy.
Future
research
should
focus
refining
modulation
strategies,
assessing
profiles
during
treatment,
employing
biomarkers
determine
optimal
dosing.
balanced
use
adverse
effects.
